/
Immunology
Seasonal Allergic Rhinitis
10
Pipeline Programs↗
14
Active Trials↗
42
Companies Involved↗
Seasonal Allergic Rhinitis is an early-stage landscape with 10 programs across 42 companies. The most active players are Shanghai Mabgeek Biotech.Co.Ltd, Longbio Pharma, Genrix (Shanghai) Biopharmaceutical Co., Ltd.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 34
Approved
No programs
Analysis
Trial Status
157
clinical trials
Completed133 · 85%
Recruiting7 · 4%
Unknown status5 · 3%
Not yet recruiting5 · 3%
Terminated3 · 2%
Withdrawn2 · 1%
Other2 · 1%
Clinical Trials
Trial Activity
157 trials
Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
Recruiting·—·Phase 2·NCT06300203·120 enrolled
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06315426·240 enrolled
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
Not yet recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07398859·300 enrolled
Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)
Completed·—·Phase 4·NCT00867191·233 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)